Niagen Bioscience, Inc.

Equities

NAGE

US1710774076

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-20 pm EDT			5-day change	1st Jan Change
13.44 ^USD	-2.47%		-1.39%	+153.35%

Jun. 09	Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting Potential Of Nicotinamide Riboside (NR) For Werner Syndrome, A Rare Genetic Disorder	RE
Jun. 09	Niagen Bioscience, Inc. Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder	CI

ChromaDex Corporation Appoints Carlos Lopez as Senior Vice President, General Counsel

Published on 07/22/2024 at 08:34

ChromaDex Corporation announces the appointment of Carlos Lopez as Senior Vice President, General Counsel. Mr. Lopez will oversee the organization's legal function, including corporate governance, securities, intellectual property, and litigation. Effective July 22, 2024, he will report directly to Rob Fried, CEO of ChromaDex and Founder of Tru Niagen®.

Carlos Lopez is a distinguished legal professional and executive leader with expertise in the dietary supplements industry. Prior to joining ChromaDex, he served as the Vice President, General Counsel at The Vitamin Shoppe, where he provided strategic legal guidance and management of corporate legal affairs. Additionally, Lopez has served on the board of The Natural Products Association, the largest and oldest nonprofit organization dedicated to the natural products industry.

Latest news about Niagen Bioscience, Inc.

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting Potential Of Nicotinamide Riboside (NR) For Werner Syndrome, A Rare Genetic Disorder	Jun. 09	RE
Niagen Bioscience, Inc. Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder	Jun. 09	CI
Canaccord Genuity Initiates Niagen Bioscience at Buy With $13 Price Target	May. 27	MT
Niagen Bioscience, Inc., Q1 2025 Earnings Call, May 07, 2025	May. 07
Niagen Bioscience, Inc. Increases Revenue Guidance for the Year 2025	May. 07	CI
Niagen Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 07	CI
Niagen Bioscience, Inc. Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Nearly 600 Clinics Nationwide	May. 05	CI
Niagen Bioscience Welcomes Pinchas Cohen To Scientific Advisory Board	Apr. 29	RE
Niagen Bioscience, Inc. Appoints Pinchas Cohen to Scientific Advisory Board	Apr. 29	CI
Niagen Bioscience Confirms Its Operations Remain Unaffected By New Tariffs	Apr. 07	RE
Sector Update: Health Care Stocks Slipping in Late Afternoon Trading	Apr. 07	MT
Sector Update: Health Care Stocks Slipping in Afternoon Trading	Apr. 07	MT
Niagen Says Its Operations Remain Resilient Amid Recent Tariff Developments	Apr. 07	MT
Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments	Apr. 07	RE
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms	Mar. 20	CI
ChromaDex Completes Name Change to Niagen Bioscience	Mar. 19	MT
ChromaDex Corporation will Change its Name to Niagen Bioscience, Inc	Mar. 19	CI
ChromaDex Corporation will Change its Ticker to NAGE from CDXC	Mar. 19	CI
Chromadex announces name change and new ticker symbol effective March 19	Mar. 13	RE
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results	Mar. 04	RE
ChromaDex Corporation, Q4 2024 Earnings Call, Mar 04, 2025	Mar. 04
ChromaDex Corporation Provides Revenue Guidance for the Year 2025	Mar. 04	CI
ChromaDex Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	Mar. 04	CI
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide	Nov. 07	CI
Earnings Flash (CDXC) CHROMADEX CORPORATION Posts Q3 Revenue $25.6M	24-10-31	MT

Chart Niagen Bioscience, Inc.

Duration

Period

NAGE: Dynamic Chart

Company Profile

Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.

Employees

104

Sector

Biotechnology & Medical Research

Calendar

Jun. 24 - Annual General Meeting

More about the company